ESS2

Across TCGA pan-cancer cohorts, ESS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ESS2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ESS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ESS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where ESS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	1.000	0.834	.001	16	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LSCC	OS	Quartile	All	0.931	0.718	.023	7	view →
OV	DFS	Median	All	1.000	0.680	.024	4	view →
CCRCC	OS	Tertile	III,IV	0.676	1.000	.016	3	view →
LUAD	OS	Quartile	II,III,IV	0.299	0.705	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ESS2–HNSC (DFS)

Open the HNSC breakdown →